Patients with human epidermal growth factor receptor 2-positive early breast cancer (HER2+ eBC) are particularly at risk for cardiotoxicity, because modern treatment schedules for this tumor rely on two antineoplastic agent classes of significant cardiotoxic potential, namely, anthracyclines and HER2-targeted therapies (2, 3). This evidence concerns the gene ERBB2 and neoplasm.